Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ADU-623

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

Immunostimulant

Related drugs:

tirvalimogene teraplasmid (2)

Histone H3.3-K27M Neoantigen Vaccine Therapy (1)

sipuleucel-T (1)

Versamune HPV (1)

APVAC1 vaccine (0)

Ad-CCL21-DC (0)

AdHER2/neu DC Vaccine (0)

bioengineered allogeneic immune cells (0)

velimogene aliplasmid (0)

BCG vaccine (0)

BN-Brachyury (0)

interferon alpha 2b (0)

dasiprotimut-T (0)

CD25hi Treg depleted DLI (0)

Escherichia coli (0)

celmoleukin (0)

recombinant human papillomavirus bivalent vaccine (0)

dendritic cell vaccine (0)

cancer vaccine MUC-1 (0)

DC-AdGMCAIX (0)

autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)

DI Leu16 IL-2 (0)

DNAJB1-PRKACA peptide vaccine (0)

Dendritic cell renal cell carcinoma fusion vaccine (0)

FR Alpha Peptide Vaccine (0)

Fusion-VAC-XS15 (0)

GSK2130579A (0)

GSK2302032A (0)

GVAX leukemia vaccine (0)

GVAX lung cancer vaccine (0)

types 6, 11, 16, 18 (0)

human papillomavirus 9-valent vaccine, recombinant (0)

H1299 cell lysate with iscomatrix adjuvant vaccine (0)

H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)

HER-2 pulsed DC1 (0)

HER2- and HER3-primed dendritic cells (0)

HRXG-K-1939 (0)

IDH1R132H peptide vaccine (0)

autologous γδ T lymphocytes (0)

KRAS peptide vaccine (0)

axalimogene filolisbac (0)

MVA-BN-Brachyury IV vaccine (0)

autologous dendritic cell vaccine (0)

NEO_PLIN2101 (0)

NUMARZU-001 (0)

NY-ESO-1 Iscomatrix (0)

NY-ESO-1 combined with MPLA vaccine (0)

ruxotemitide (0)

PEG IFN-a 2b (0)

PF-06753512 (0)

PF-07263689 (0)

PNV21 vaccine (0)

Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)

PolyPEPI 1018 (0)

rilimogene galvacirepvec (0)

RNA-NP vaccine (0)

HSP Gp96 vaccine (0)

BCG vaccine (0)

SQZ-PBMC-HPV (0)

TG01 vaccine (0)

TVI-Brain-1 (0)

EGFREDVmiR-16 (0)

live attenuated bacillus Calmette-Guerin (0)

CMV-MVA vaccine (0)

Undisclosed VLP vaccine (0)

Undisclosed ovarian cancer vaccine (0)

VV-GMCSF-Lact (0)

alpha-tocopheroloxyacetic acid (0)

astuprotimut-R (0)

aDC1 vaccine (0)

allogeneic K562-GM tumor cell vaccine (0)

allogeneic Myeloma GM-CSF Vaccine (0)

alpha-lactalbumin vaccine (0)

autologous Tcm cellular immunotherapy (0)

autologous formalin-fixed tumor vaccine (0)

gp96-Ig vaccine (0)

iNeo-Vac-P01 (0)

iNeo-Vac-R01 (0)

mammaglobin-A DNA vaccine (0)

multi-epitope melanoma peptide (0)

neoantigen DNA vaccine (0)

neoantigen peptide vaccine (0)

nonavalent HPV vaccine (0)

oral therapeutic vaccine V3-X (0)

p.DOM-WT1-126 DNA vaccine (0)

pING-hHER3FL (0)

polyvalent vaccine-KLH conjugate (0)

self-amplifying RNA cancer vaccine (0)

›

Phase I Study of Safety and Immunogenicity of ADU-623 (NCT01967758)

Phase 1

Providence Health & Services

Providence Health & Services

Completed

Phase 1

Providence Health & Services

Completed

Last update posted :

08/17/2018

Initiation :

01/08/2014

Primary completion :

06/18/2018

Completion :

08/15/2018

CTAG1B

|

ADU-623